Teva’s (TEVA) $125 Million BioXcel Bid Offers Upside, but FDA and Auction Risks Remain
Yahoo Finance· Sep 12, 2026 · 4:57 PM
This is a summary. Read the complete story at Yahoo Finance below.
Read full article at Yahoo FinanceRelated Stories
marketsabout 4 hours ago
AT&T’s stock looks like the smartest bet in the wireless sector, analyst says
An analyst at BNP has taken a positive view of AT&T’s stock, writing that investors should have “little to quibble with on the mobile side.”
MarketWatch
marketsabout 5 hours ago
Bitcoin hits an 8-month high — and sends a clear message about risk appetite right now
The lack of clarity around crypto’s regulatory framework hasn’t stopped bitcoin from surging, as investors haven’t abandoned hopes for clearer U.S. rules.
MarketWatch
marketsabout 5 hours ago
As the S&P 500 nears a new record high, there are signs of weakness below the surface
About 60% of the stocks in the S&P 500 are down more than 20% from their all-time highs.
MarketWatch